Valerie Archer, APRN
Psychiatry · Las Vegas, NVNPI 1881240216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 505 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$1K
- Alkermes, Inc.$990
- Neurocrine Biosciences, Inc.$838
- plus $3K from 20 others
What the payments were for
- Food & beverage$10,14298%
- Education$2122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,678 |
| Otsuka America Pharmaceutical, Inc. | 94 | $1,648 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 86 | $1,629 |
| Johnson & Johnson | 39 | $1,044 |
| Alkermes, Inc. | 44 | $990 |
| Neurocrine Biosciences, Inc. | 39 | $838 |
| E.r. Squibb & Sons, L.L.C. | 28 | $553 |
| Teva Pharmaceuticals USA, Inc. | 17 | $340 |
| Sunovion Pharmaceuticals Inc. | 19 | $317 |
| Almatica Pharma LLC | 17 | $219 |
| Lundbeck LLC | 11 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $187 |
| Vanda Pharmaceuticals Inc. | 7 | $137 |
| Avanir Pharmaceuticals, Inc. | 5 | $103 |
| Eisai Inc. | 5 | $98 |
| Bausch Health US, LLC | 4 | $80 |
| Indivior Inc. | 3 | $71 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Corium, LLC | 2 | $18 |
| Neuronetics, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$617
- INGREZZA$175
- INVEGA SUSTENNA$153
- CAPLYTA$126
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- REXULTI$124
- COBENFY$108
How this compares
$10,354 in reported general payments places this provider in the 90th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 45 | $374,783 |
| Austedo XrDeutetrabenazine | 17 | $210,671 |
| Invega SustennaPaliperidone Palmitate | 51 | $152,770 |
| Abilify MaintenaAripiprazole | 35 | $96,677 |
| VraylarCariprazine Hcl | 46 | $67,144 |
| RexultiBrexpiprazole | 18 | $42,040 |
| CaplytaLumateperone Tosylate | 21 | $35,397 |
| Lurasidone Hcl | 79 | $27,931 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $17,866 |
| BelsomraSuvorexant | 31 | $13,331 |
| Aripiprazole | 317 | $12,752 |
| QuviviqDaridorexant Hcl | 24 | $11,592 |
| Quetiapine Fumarate | 642 | $8,615 |
| Divalproex Sodium ErDivalproex Sodium | 86 | $4,415 |
| DayvigoLemborexant | 13 | $4,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $838 | $374,78345 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $340 | $210,67117 claims |
| Johnson & JohnsonInvega Sustenna | $1,044 | $152,77051 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,648 | $138,71753 claims |
| AbbVieVraylar | $1,678 | $67,14446 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,629 | $35,39721 claims |
| Alkermes, Inc.Lybalvi | $990 | $17,86612 claims |
| Eisai Inc.Dayvigo | $98 | $4,40613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Dylan WintLas Vegas$86K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.